Revolution Medicines (RVMD) Insider Trading & Ownership $34.95 -1.72 (-4.69%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$35.28 +0.33 (+0.96%) As of 09:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Revolution Medicines (NASDAQ:RVMD) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage8.20%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$60.00MNumber OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$7.85M Get RVMD Insider Trade Alerts Want to know when executives and insiders are buying or selling Revolution Medicines stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address RVMD Insider Buying and Selling by Quarter Revolution Medicines Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails3/17/2025Jack AndersCFOSell1,864$39.04$72,770.56 3/17/2025Margaret A HornCOOSell3,058$39.04$119,384.32 3/17/2025Mark A GoldsmithInsiderSell11,738$39.04$458,251.52 12/16/2024Jack AndersCFOSell2,635$45.40$119,629.00 12/16/2024Margaret A HornCOOSell4,329$45.40$196,536.60 12/16/2024Mark A GoldsmithInsiderSell11,714$45.40$531,815.60 12/5/2024Thilo SchroederDirectorBuy1,304,347$46.00$59,999,962.00 10/14/2024Stephen Michael KelseyInsiderSell16,666$49.49$824,800.34 10/11/2024Jack AndersCFOSell10,000$50.30$503,000.00 10/11/2024Jeff CisliniGeneral CounselSell6,000$50.17$301,020.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 10/11/2024Margaret A HornCOOSell50,000$50.34$2,517,000.00 10/11/2024Mark A GoldsmithInsiderSell30,000$50.36$1,510,800.00 10/8/2024Barbara WeberDirectorSell5,200$48.02$249,704.00 10/1/2024Mark A GoldsmithInsiderSell10,000$44.93$449,300.00 (Data available from 1/1/2013 forward) RVMD Insider Trading Activity - Frequently Asked Questions Who is on Revolution Medicines' Insider Roster? The list of insiders at Revolution Medicines includes Barbara Weber, Jack Anders, Jeff Cislini, Margaret A Horn, Mark A Goldsmith, Stephen Michael Kelsey, Sushil Patel, Thilo Schroeder, and Xiaolin Wang. Learn more on insiders at RVMD. What percentage of Revolution Medicines stock is owned by insiders? 8.20% of Revolution Medicines stock is owned by insiders. Learn more on RVMD's insider holdings. Which Revolution Medicines insiders have been buying company stock? The following insider purchased RVMD shares in the last 24 months: Thilo Schroeder ($59,999,962.00). How much insider buying is happening at Revolution Medicines? Insiders have purchased a total of 1,304,347 RVMD shares in the last 24 months for a total of $59,999,962.00 bought. Which Revolution Medicines insiders have been selling company stock? The following insiders have sold RVMD shares in the last 24 months: Barbara Weber ($775,754.00), Jack Anders ($1,927,173.81), Jeff Cislini ($761,225.77), Margaret A Horn ($4,716,677.08), Mark A Goldsmith ($6,064,290.62), Stephen Michael Kelsey ($3,286,660.83), and Sushil Patel ($174,555.00). How much insider selling is happening at Revolution Medicines? Insiders have sold a total of 445,045 Revolution Medicines shares in the last 24 months for a total of $17,706,337.11 sold. Revolution Medicines Key ExecutivesDr. Mark A. Goldsmith Ph.D. (Age 62)CEO, President & Chairman Compensation: $1.12MMr. Jack Anders (Age 47)Chief Financial Officer Compensation: $665.28k1 recent tradesMs. Margaret A. Horn J.D. (Age 61)Chief Operating Officer Compensation: $811.08k1 recent tradesDr. Stephen M. Kelsey FRC Path. (Age 63)FRCP, M.D., President of Research & Development Compensation: $812.17kMs. Xiaolin Wang (Age 53)Executive Vice President of Development Compensation: $633.74kDr. Martin D. Burke M.D.Ph.D., Co-Founder & Chairman of Scientific Advisory BoardDr. Michael A. Fischbach Ph.D. (Age 43)Academic Co-Founder & Member of Scientific Advisory Board Dr. Kevan M. Shokat Ph.D.Academic Co-Founder & Member of Scientific Advisory BoardMr. Walter Reiher Ph.D.Chief Information OfficerMs. Jan Smith Ph.D.Chief Scientific Officer More Insider Trading Tools from MarketBeat Related Companies BNTX Insider Selling SMMT Insider Selling INSM Insider Selling TEVA Insider Selling GMAB Insider Selling MRNA Insider Selling VTRS Insider Selling BBIO Insider Selling VRNA Insider Selling BPMC Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Strategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months This page (NASDAQ:RVMD) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revolution Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
